PE20110772A1 - ESPIRO AZEPAN OXAZOLIDINONAS COMO BLOQUEADORES DEL CANAL DE POTASIO Kv1.3 - Google Patents
ESPIRO AZEPAN OXAZOLIDINONAS COMO BLOQUEADORES DEL CANAL DE POTASIO Kv1.3Info
- Publication number
- PE20110772A1 PE20110772A1 PE2011001198A PE2011001198A PE20110772A1 PE 20110772 A1 PE20110772 A1 PE 20110772A1 PE 2011001198 A PE2011001198 A PE 2011001198A PE 2011001198 A PE2011001198 A PE 2011001198A PE 20110772 A1 PE20110772 A1 PE 20110772A1
- Authority
- PE
- Peru
- Prior art keywords
- oxazolidinones
- azepan
- spiro
- channel blockers
- potassium channel
- Prior art date
Links
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 title abstract 2
- 102100034355 Potassium voltage-gated channel subfamily A member 3 Human genes 0.000 title abstract 2
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 title abstract 2
- 239000003450 potassium channel blocker Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical group 0.000 abstract 2
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 230000007823 neuropathy Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Child & Adolescent Psychology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
SE REFIERE A COMPUESTOS DERIVADOS DE ESPIRO AZEPAN OXAZOLIDINONAS (1-OXA-3,8-DIAZAESPIRO[4.6]UNDECAN-2-ONAS) DE FORMULA (1) DONDE R1 Y R2 SON CADA UNO H, F, CF3 O ALQUILO(C1-C3); n ES DE 0 A 2; R3 ES HALOGENO, ALQUILO(C1-C3), CN, NH2, ENTRE OTROS; m ES DE 0 A 3; R4 ES HALOGENO, CN, OH, OCH3, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: (5S)-8-[3,5-BIS(TRIFLUOROMETIL)BENZOIL]-3-[(1S)-1-FENILETIL]-1-OXA-3,8-DIAZAESPIRO[4.6]-UNDECAN-2-ONA; (5R)-8-[3-CIANOBENZOIL]-3-[(1S)-1-FENILETIL]-1-OXA-3,8-DIAZAESPIRO[4.6]UNDECAN-ONA; ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON BLOQUEADORES DEL CANAL DE POTASIO Kv1.3 VOLTAJE DEPENDIENTE SIENDO UTILES EN EL TRATAMIENTO DE DIABETES, NEUROPATIAS INFLAMATORIAS, ARTRITIS REUMATOIDE, ESCLEROSIS MULTIPLE
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12191308P | 2008-12-12 | 2008-12-12 | |
| EP08171421 | 2008-12-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20110772A1 true PE20110772A1 (es) | 2011-10-19 |
Family
ID=40513443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2011001198A PE20110772A1 (es) | 2008-12-12 | 2009-12-10 | ESPIRO AZEPAN OXAZOLIDINONAS COMO BLOQUEADORES DEL CANAL DE POTASIO Kv1.3 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8575148B2 (es) |
| EP (1) | EP2376501A1 (es) |
| JP (1) | JP2012511546A (es) |
| KR (1) | KR20110110165A (es) |
| CN (1) | CN102333782A (es) |
| AR (1) | AR074558A1 (es) |
| AU (1) | AU2009324358A1 (es) |
| BR (1) | BRPI0922714A2 (es) |
| CA (1) | CA2743557A1 (es) |
| CO (1) | CO6390036A2 (es) |
| CR (1) | CR20110302A (es) |
| DO (1) | DOP2011000164A (es) |
| EA (1) | EA201170801A1 (es) |
| EC (1) | ECSP11011118A (es) |
| IL (1) | IL212948A0 (es) |
| MX (1) | MX2011006221A (es) |
| PE (1) | PE20110772A1 (es) |
| TW (1) | TW201026708A (es) |
| WO (1) | WO2010066840A1 (es) |
| ZA (1) | ZA201104041B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1201048A1 (en) | 2011-10-03 | 2015-08-21 | The Regents Of The University Of California | Treatment of obesity and obesity-related disorders by pharmacological targeting of kv1.3 potassium channels |
| KR20150075091A (ko) * | 2012-10-29 | 2015-07-02 | 에프. 호프만-라 로슈 아게 | 3,4-이치환된 옥사졸리디논 유도체 및 칼슘 활성화 칼륨 채널의 억제제로서 이의 용도 |
| TWI701249B (zh) | 2015-03-13 | 2020-08-11 | 德商４Ｓｃ製藥公司 | Ｋv１.３抑制劑及其醫學應用 |
| TWI698438B (zh) | 2015-03-13 | 2020-07-11 | 德商４Ｓｃ製藥公司 | Ｋv１.３抑制劑及其醫學應用 |
| CN109053751A (zh) * | 2018-08-30 | 2018-12-21 | 成都海博锐药业有限公司 | 具有螺环结构的fxr调节剂 |
| WO2020252130A1 (en) * | 2019-06-12 | 2020-12-17 | Lieber Institute, Inc. | Kv11.1-3.1 inhibiting methods and compositions |
| KR20220079575A (ko) * | 2019-10-07 | 2022-06-13 | 디.이. 쇼우 리서치, 엘엘씨 | Kv1.3 칼륨 셰이커 채널 차단제로서의 아릴 헤테로비시클릭 화합물 |
| WO2021071812A1 (en) * | 2019-10-07 | 2021-04-15 | D.E Shaw Research, Llc | Arylmethylene heterocyclic compounds as kv1.3 potassium shaker channel blockers |
| JP7780440B2 (ja) * | 2019-10-07 | 2025-12-04 | ディー．イー．ショウ リサーチ，エルエルシー | Ｋｖ１．３カリウムシェーカーチャネル遮断薬としてのアリール複素二環式化合物 |
| CN111574537B (zh) * | 2020-05-20 | 2022-11-15 | 成都药明康德新药开发有限公司 | 叔丁基-8-氧杂-3,11-二氮杂螺[5.6]十二烷-3-甲酸基酯的合成方法 |
| AU2022364718A1 (en) * | 2021-10-13 | 2024-05-16 | Vanqua Bio, Inc. | Small molecule modulators of glucocerebrosidase activity and uses thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6303637B1 (en) | 1998-10-30 | 2001-10-16 | Merck & Co., Inc. | Heterocyclic potassium channel inhibitors |
-
2009
- 2009-12-09 TW TW098142079A patent/TW201026708A/zh unknown
- 2009-12-09 AR ARP090104760A patent/AR074558A1/es unknown
- 2009-12-10 BR BRPI0922714A patent/BRPI0922714A2/pt not_active IP Right Cessation
- 2009-12-10 EA EA201170801A patent/EA201170801A1/ru unknown
- 2009-12-10 CA CA2743557A patent/CA2743557A1/en not_active Abandoned
- 2009-12-10 KR KR1020117016047A patent/KR20110110165A/ko not_active Withdrawn
- 2009-12-10 US US13/133,042 patent/US8575148B2/en not_active Expired - Fee Related
- 2009-12-10 JP JP2011540106A patent/JP2012511546A/ja active Pending
- 2009-12-10 EP EP09765127A patent/EP2376501A1/en not_active Withdrawn
- 2009-12-10 WO PCT/EP2009/066836 patent/WO2010066840A1/en not_active Ceased
- 2009-12-10 AU AU2009324358A patent/AU2009324358A1/en not_active Abandoned
- 2009-12-10 PE PE2011001198A patent/PE20110772A1/es not_active Application Discontinuation
- 2009-12-10 MX MX2011006221A patent/MX2011006221A/es not_active Application Discontinuation
- 2009-12-10 CN CN2009801494792A patent/CN102333782A/zh active Pending
-
2011
- 2011-05-17 IL IL212948A patent/IL212948A0/en unknown
- 2011-05-31 ZA ZA2011/04041A patent/ZA201104041B/en unknown
- 2011-05-31 DO DO2011000164A patent/DOP2011000164A/es unknown
- 2011-06-03 CR CR20110302A patent/CR20110302A/es not_active Application Discontinuation
- 2011-06-08 CO CO11070889A patent/CO6390036A2/es not_active Application Discontinuation
- 2011-06-09 EC EC2011011118A patent/ECSP11011118A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20110237569A1 (en) | 2011-09-29 |
| EA201170801A1 (ru) | 2011-12-30 |
| US8575148B2 (en) | 2013-11-05 |
| ZA201104041B (en) | 2012-11-28 |
| TW201026708A (en) | 2010-07-16 |
| CO6390036A2 (es) | 2012-02-29 |
| EP2376501A1 (en) | 2011-10-19 |
| AR074558A1 (es) | 2011-01-26 |
| KR20110110165A (ko) | 2011-10-06 |
| WO2010066840A1 (en) | 2010-06-17 |
| MX2011006221A (es) | 2011-06-28 |
| DOP2011000164A (es) | 2011-06-30 |
| BRPI0922714A2 (pt) | 2016-01-05 |
| AU2009324358A1 (en) | 2011-06-23 |
| CR20110302A (es) | 2011-10-27 |
| ECSP11011118A (es) | 2011-07-29 |
| IL212948A0 (en) | 2011-07-31 |
| CN102333782A (zh) | 2012-01-25 |
| CA2743557A1 (en) | 2010-06-17 |
| JP2012511546A (ja) | 2012-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20110772A1 (es) | ESPIRO AZEPAN OXAZOLIDINONAS COMO BLOQUEADORES DEL CANAL DE POTASIO Kv1.3 | |
| PE20081776A1 (es) | Moduladores 2-aminopirimidina del receptor histamina h4 | |
| PE20141004A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| PE20090222A1 (es) | Compuestos [6,6] y [6,7]-biciclicos como agonistas del receptor acoplado a la proteina g gpr119 | |
| PE20081753A1 (es) | Compuestos y composiciones como inhibidores de la proteasa activadora de canal | |
| PE20142452A1 (es) | AMIDAS CICLICAS COMO INHIBIDORES DE MetAP-2 | |
| PE20110028A1 (es) | Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato | |
| PE20141005A1 (es) | 1,3-oxazinas como inhibidores de bace1 y/o bace2 | |
| PE20131197A1 (es) | Compuestos de pirazolopirimidina como inhibidores de jak y composiciones farmaceuticas que los contienen | |
| PE20110150A1 (es) | Amidofenoxiindazoles como inhibidores de c-met | |
| PE20071311A1 (es) | Compuestos 8-azabiciclo[3.2.1]octano como antagonistas del receptor opioide mu | |
| PE20140240A1 (es) | Antagonistas del receptor del cgrp de piperidinona carboxamida azaindano | |
| PE20141588A1 (es) | Nuevos derivados de [1,2,3]triazolo[4,5-d]pirimidina como agonistas del receptor de canabinoides 2 | |
| PE20130576A1 (es) | Compuestos heterociclicos de nitrogeno utiles como inhibidores de pde10 | |
| PE20120833A1 (es) | Compuestos sustituidos de espiro-amida | |
| PE20070720A1 (es) | Derivados de fenilo como antagonistas del receptor 3 de la histamina | |
| PE20121639A1 (es) | Derivados de 3-hidroxi-5-arilizotiazol como moduladores de gpr40 | |
| PE20140161A1 (es) | Compuesto biciclico | |
| PE20140302A1 (es) | Inhibidores del virus de la hepatitis c | |
| PE20141685A1 (es) | Novedosas dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de transtornos inflamatorios | |
| PE20110819A1 (es) | Compuestos de carbazol carboxamida utiles como inhibidores de cinasa | |
| PE20081229A1 (es) | Antagonistas de receptor de orexina de diazepam sustituido | |
| PE20131343A1 (es) | Derivados de acido benzoico | |
| PE20120780A1 (es) | Nicotinamida sustituida como moduladores kcnq2/3 | |
| PE20161396A1 (es) | Compuesto heterociclico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |